Phase 1Completed
Assessment of Effect of Rapastinel on Driving Performance
A Phase 1, Randomized, Double-blind, Double-dummy, Placebo-controlled, 5-period, Crossover Study Assessing the Effects of Rapastinel Compared to Alprazolam, Ketamine, and Placebo on Simulated Driving Performance in Normal Healthy Participants
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc (Industry)
- Enrollment
- 107 enrolled
- Conditions
- Driving Performance
- Interventions
- Rapastinel; Alprazolam; Ketamine; Rapastinel Matched Placebo; Alprazolam Matched Placebo; Ketamine Matched Placebo
- Ages
- adults, older adults
- Registry
- NCT03814733
Full record on ClinicalTrials.gov
From the registry
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.
Primary outcomes
- Simulated driving performance as measured by SDLP using the CRCDS-MiniSim for rapastinel compared with placebo and positive control (alprazolam)
History
Last registry update
Study completion
Primary completion
Registered
Started